Nuevocor, a pre-clinical stage biotechnology company, announced on Thursday that it has named Dr John Lee, MD, PhD, as its new chief Medical officer.
Dr Lee, a life science executive, has more than 15 years of clinical development and regulatory experience from early drug discovery to late-stage clinical development. He has most recently served as the chief medical officer of PhaseBio Pharmaceuticals. He has served as vice president, global head, Cardiovascular Center of Excellence at Quintiles and executive director, Discovery Medicine at Bristol-Myers Squibb, and has served in leadership roles in both biotech and pharmaceutical sectors.
Dr Yann Chong Tan, PhD, CEO and co-founder of Nuevocor, said, 'Dr Lee's appointment marks a significant milestone for Nuevocor. His extensive experience and proven track record in clinical development make him the ideal candidate to lead our clinical development team. His leadership will be instrumental in furthering our commitment to advancing science and translating it into therapies that will make a real difference in patients' lives.'
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne